Current Scheduling Status
None
Year(s) and type of review / ECDD meetings
Drug Class
Recommendation (from TRS)
Substance identification
Phenallymal (CAS-115-43-5), chemically _ 5-allyl-5-pheny]-barbituric acid, is also known as alphenal, phenallymalum, and prophenal. The substance is a racemic mixture.
Similarity to known substances and effects on the CNS
Information on the general pharmacology of phenallymal is not available. One may assume from its clinical use as a sedative—hypnotic that- it may have a profile similar to that of other
intermediate-acting barbiturates such as pentobarbital. Its metabolism was studied as one of a series of allyl barbiturates and it did not differ from other members of the series. There is almost a complete lack of data in animals and man concerning the effects of phenallymal on the central nervous system.
Dependence potential
There is no information on the ability. of phenallymal to induce physical or psychic dependence in either animals or man in controlled laboratory studies.
Actual abuse and or/evidence of likelihood of abuse
There have been no reports on the abuse of phenallymal. The drug is under national control in five countries. There have been no reports of illicit manufacture, illicit trafficking, or seizures of the drug.
Therapeutic usefulness
Phenallymal has been recommended as a sedative and hypnoticbut no details on its therapeutic usefulness have been found. Thereis little evidence that the compound is currently being manufactured or sold.
Recommendation
The Committee found that there was insufficient evidence thatphenallymal is being, or is likely to be, abused so as to constitute a public health and social problem warranting the placing of the substance under international control. On the basis of the very limited data concerning its pharmacological profile. dependence potential, and actual abuse, the
Committee rated the likelihood of abuse of phenallymal as indeterminate. The degree of public health and social problems associated with the drug was found to be low as was its therapeutic usefulness. In the light of this assessment, the Committee recommended against scheduling of the drug.
Phenallymal (CAS-115-43-5), chemically _ 5-allyl-5-pheny]-barbituric acid, is also known as alphenal, phenallymalum, and prophenal. The substance is a racemic mixture.
Similarity to known substances and effects on the CNS
Information on the general pharmacology of phenallymal is not available. One may assume from its clinical use as a sedative—hypnotic that- it may have a profile similar to that of other
intermediate-acting barbiturates such as pentobarbital. Its metabolism was studied as one of a series of allyl barbiturates and it did not differ from other members of the series. There is almost a complete lack of data in animals and man concerning the effects of phenallymal on the central nervous system.
Dependence potential
There is no information on the ability. of phenallymal to induce physical or psychic dependence in either animals or man in controlled laboratory studies.
Actual abuse and or/evidence of likelihood of abuse
There have been no reports on the abuse of phenallymal. The drug is under national control in five countries. There have been no reports of illicit manufacture, illicit trafficking, or seizures of the drug.
Therapeutic usefulness
Phenallymal has been recommended as a sedative and hypnoticbut no details on its therapeutic usefulness have been found. Thereis little evidence that the compound is currently being manufactured or sold.
Recommendation
The Committee found that there was insufficient evidence thatphenallymal is being, or is likely to be, abused so as to constitute a public health and social problem warranting the placing of the substance under international control. On the basis of the very limited data concerning its pharmacological profile. dependence potential, and actual abuse, the
Committee rated the likelihood of abuse of phenallymal as indeterminate. The degree of public health and social problems associated with the drug was found to be low as was its therapeutic usefulness. In the light of this assessment, the Committee recommended against scheduling of the drug.
ECDD Recommendation
Scheduling/control not currently recommended
Link to full TRS
who_trs_741.pdf2.21 MB